Brachytherapy boost for prostate cancer: Trends in care and survival outcomes.
Androgen suppression combined with elective nodal and dose-escalated radiation therapy recently demonstrated an improved biochemical failure-free survival in men who received external beam radiation therapy (EBRT) plus a brachytherapy boost (BB) compared with dose-escalated external beam radiotherapy (DE-EBRT). We sought to analyze the factors predictive for use of EBRT + BB as compared with DE-EBRT and report resulting survival outcomes on a national level using a hospital-based registry.



We identified 113,719 men from the National Cancer Database from 2004 to 2013 with intermediate- or high-risk prostate cancer who were treated with EBRT + BB or DE-EBRT. We performed univariate and multivariate analyses of all available factors potentially predictive of receipt of treatment selection. Survival was evaluated in a multivariable model with propensity adjustment.



For intermediate-risk patients, utilization of BB decreased from 33.1% (n = 1742) in 2004 to 12.5% (n = 766) in 2013 and for high-risk patients, utilization dropped from 27.6% (n = 879) to 10.8% (n = 479). Numerous factors predictive for use of BB were identified. Cox proportional hazards analysis was performed-adjusting for age, Charlson-Deyo comorbidity score, T stage, prostate-specific antigen, Gleason score, and sociodemographic factors-and demonstrated BB use was associated with a hazard ratio of 0.71 (95% confidence interval, 0.67-0.75; p < 0.0005) and 0.73 (95% confidence interval, 0.68-0.78; p < 0.0005) for intermediate- and high-risk patients, respectively.



There has been a concerning decline in the utilization of BB for intermediate- and high-risk prostate cancer patients despite an association with improved on overall survival. Numerous factors predictive for use of BB have been identified.
Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA.
S M
SM
Glaser
Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
M J
MJ
Dohopolski
Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA.
G K
GK
Balasubramani
Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA.
R M
RM
Benoit
Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA.
R P
RP
Smith
Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA. Electronic address: beriwals@upmc.edu.
S
S
Beriwal
D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D001918:Brachytherapy / Q000379:methods* / Q000706:statistics & numerical data / Q000639:trends; D017024:Chemotherapy, Adjuvant; D016208:Databases, Factual; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D060787:Neoplasm Grading; D016016:Proportional Hazards Models; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D012959:Socioeconomic Factors; D016019:Survival Analysis; D016896:Treatment Outcome
D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen
Brachytherapy boost; EBRT; NCDB; Prostate cancer